Skip to main content

Table 4 Sensitivity and specificity of HepaClear in different subgroups from the validation set

From: HepaClear, a blood-based panel combining novel methylated CpG sites and protein markers, for the detection of early-stage hepatocellular carcinoma

Subgroup

Sensitivity (95% CI) (%)

Specificity (95% CI) (%)

Male (n = 149)

85.4 (75.8–92.2)

91.0 (81.5–96.6)

CHB (n = 153)

83.0 (73.8–90.0)

89.2 (79.1–95.6)

Cirrhosis (n = 130)

85.6 (76.7–91.7)

90.0 (76.3–97.2)

AFP < 20 ng/mL (n = 134)

67.5 (50.9–81.4)

92.6 (85.3–97.0)

  1. AFP a-fetoprotein, CHB chronic hepatitis B, CI confidence interval
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us